Found: 15
Select item for more details and to access through your institution.
Efficacy and safety of crisaborole in patients with mild-tomoderate atopic dermatitis and other atopic comorbidities.
- Published in:
- Allergy & Asthma Proceedings, 2021, v. 42, n. 5, p. 425, doi. 10.2500/aap.2021.42.210064
- By:
- Publication type:
- Article
A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
- Published in:
- Modern Rheumatology, 2013, v. 23, n. 4, p. 623, doi. 10.3109/s10165-012-0742-6
- By:
- Publication type:
- Article
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
- Published in:
- Rheumatology, 2024, v. 63, n. 1, p. 140, doi. 10.1093/rheumatology/kead183
- By:
- Publication type:
- Article
Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 4, p. 951, doi. 10.1007/s13555-023-00899-y
- By:
- Publication type:
- Article
Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 185, doi. 10.1007/s13555-021-00646-1
- By:
- Publication type:
- Article
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 5, p. 1667, doi. 10.1007/s13555-021-00584-y
- By:
- Publication type:
- Article
Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 3, p. 845, doi. 10.1007/s13555-021-00509-9
- By:
- Publication type:
- Article
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis.
- Published in:
- Pediatric Dermatology, 2020, v. 37, n. 6, p. 1030, doi. 10.1111/pde.14328
- By:
- Publication type:
- Article
288 Once-daily crisaborole as a long-term maintenance treatment in patients with mild-to-moderate atopic dermatitis: A 52-week clinical trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii2, doi. 10.1093/bjd/ljac140.004
- By:
- Publication type:
- Article
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 4, p. 623, doi. 10.1007/s40257-023-00780-w
- By:
- Publication type:
- Article
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
- Published in:
- American Journal of Clinical Dermatology, 2020, v. 21, n. 2, p. 275, doi. 10.1007/s40257-020-00510-6
- By:
- Publication type:
- Article
Etanercept Withdrawal and Re-Treatment in Non-Radiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label, Phase IV Trial.
- Published in:
- Journal of Rheumatology, 2023, v. 50, n. 4, p. 478, doi. 10.3899/jrheum.220353
- By:
- Publication type:
- Article
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
- Published in:
- Clinical Rheumatology, 2018, v. 37, n. 8, p. 2043, doi. 10.1007/s10067-018-4077-3
- By:
- Publication type:
- Article
Early Cognitive Dysfunction in Elderly Patients after Total Knee Arthroplasty: An Analysis of Risk Factors and Cognitive Functional Levels.
- Published in:
- BioMed Research International, 2022, p. 1, doi. 10.1155/2022/5372603
- By:
- Publication type:
- Article